LINO M

Linagliptin INN & Metformin Hcl BP

DIABETES » DPP-4 INHIBITORS & BIGUANIDE

INDICATION

Lino-M tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

DOSAGE AND ADMINISTRATION

Age and Body Weight:
Adult, age over 18 years.

Dosage Guideline:

The dosage of LINO-M should be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended dose of 2.5 mg linagliptin/1000 mg metformin hydrochloride twice daily. LINO-M should be given twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with metformin use.

Renal Dosage:
Should not be taken with eGFR below 30 mL/min/1.73 m2.
Initiation is not recommended in patients with eGFR between 30 – 45 mL/min/1.73 m2

OR, AS DIRECTED BY PHYSICIAN.

COMPOSITION

Lino-M 500: Each film-coated tablet contains Linagliptin INN 2.5 mg & Metformin HCl BP 500 mg.

Lino-M 850: Each film-coated tablet contains Linagliptin INN 2.5 mg & Metformin HCl BP 850 mg.

Lino-M 1000: Each film-coated tablet contains Linagliptin INN 2.5 mg & Metformin Hydrochloride BP 1000 mg.

Lino-M XR: Each Extended Release tablet contains Linagliptin INN 5 mg & Metformin Hydrochloride BP 1000 mg.